Each dot is one of the 213 Healthcare stocks, sized by market cap. The median Revenue Growth (1y) (TTM) is 10.2% and the median P/E 24.75. Pinned to the edge: 17 outliers on X and 12 on Y.
Quadrants split at the medians. Hover a dot for its true values; click to open the company. Outliers are more than 3× the interquartile range beyond the quartiles.
| # | Industry | ||||
|---|---|---|---|---|---|
| 1 | LLYEli Lilly | 49.6% | 42.78 | $1.14T | Pharmaceuticals |
| 2 | JNJJohnson & Johnson | 7.8% | 39.77 | $640.09B | Pharmaceuticals |
| 3 | ABBVAbbVie | 10.4% | 80.24 | $506.31B | Pharmaceuticals |
| 4 | UNHUnitedhealth | 6.5% | 26.11 | $368.78B | Managed Care |
| 5 | MRKMerck | 4.6% | 109.67 | $347.97B | Pharmaceuticals |
| 6 | NVSNovartis Ag | 2.8% | 18.89 | $297.95B | Pharmaceuticals |
| 7 | AZNAstrazeneca | 9.4% | 25.39 | $265.27B | Pharmaceuticals |
| 8 | TMOThermo Fisher Scientific | 7.2% | 36.27 | $252.68B | Life Sciences Tools |
| 9 | AMGNAmgen | 9.1% | 27.26 | $238.32B | Biotechnology |
| 10 | ABTAbbott Laboratories | 8.1% | 33.32 | $180.76B | Medical Devices |
| 11 | PFEPfizer | -0.2% | 39.16 | $169.66B | Pharmaceuticals |
| 12 | DHRDanaher | 4.6% | 40.87 | $163.65B | Life Sciences Tools |
| 13 | ISRGIntuitive Surgical | 20.5% | 52.91 | $156.46B | Medical Devices |
| 14 | VRTXVertex Pharmaceuticals | 10.2% | 29.65 | $130.63B | Biotechnology |
| 15 | BMYBristol Myers Squibb | 3.1% | 13.49 | $125.26B | Pharmaceuticals |
| 16 | MDTMedtronic | 9.8% | 23.06 | $120.62B | Medical Devices |
| 17 | CVSCvs Health | 7.4% | 24.09 | $117.81B | Managed Care |
| 18 | MCKMckesson | 8.8% | 25.61 | $117.61B | Drug Distribution |
| 19 | SYKStryker | 8.5% | 31.23 | $116.46B | Medical Devices |
| 20 | GSKGsk | 87.0%OUT | 7.82 | $103.52B | Pharmaceuticals |
| 21 | HCAHCA Healthcare | 7.3% | 14.92 | $102.08B | Hospitals |
| 22 | ELVElevance Health | 3.6% | 18.18 | $93.41B | Managed Care |
| 23 | REGNRegeneron Pharmaceuticals | 9.3% | 19.05 | $82.44B | Biotechnology |
| 24 | CICigna | 7.8% | 12.51 | $80.24B | Managed Care |
| 25 | BSXBoston Scientific | 13.5% | 18.12 | $66.59B | Medical Devices |
| 26 | TAKTakeda Pharmaceutical | 0.7% | 112.01 | $64.33B | Pharmaceuticals |
| 27 | CORCencora | 5.1% | 24.25 | $63.66B | Drug Distribution |
| 28 | CAHCardinal Health | 14.2% | 34.62 | $59.34B | Drug Distribution |
| 29 | BDXBecton Dickinson | 17.4% | 57.03 | $53.66B | Medical Supplies |
| 30 | ARGXArgenx Se | 61.5% | 28.56 | $53.61B | Biotechnology |
| 31 | EWEdwards Lifesciences | 14.6% | 51.67 | $51.92B | Medical Devices |
| 32 | SNYSanofi | 27.7% | 10.91 | $50.86B | Pharmaceuticals |
| 33 | HUMHumana | 18.3% | 39.30 | $50.27B | Managed Care |
| 34 | AAgilent Technologies | 8.6% | 34.47 | $49.64B | Life Sciences Tools |
| 35 | TEVATeva Pharmaceutical Industries | 4.1% | 65.87 | $46.51B | Generic Drugs |
| 36 | IQVIqvia Holdings | 8.2% | 33.20 | $45.65B | Contract Research |
| 37 | IDXXIdexx Laboratories | 12.8% | 39.42 | $44.93B | Animal Health |
| 38 | ONCBeOne Medicines | 34.3% | 63.20 | $41.44B | Pharmaceuticals |
| 39 | ILMNIllumina | 4.9% | 49.62 | $40.94B | Life Sciences Tools |
| 40 | BIIBBiogen | 0.3% | 44.35 | $37.02B | Biotechnology |
| 41 | RMDResmed | 9.9% | 24.08 | $36.68B | Medical Devices |
| 42 | ALCAlcon | 8.5% | 53.60 | $34.46B | Medical Devices |
| 43 | ZTSZoetis | 1.5% | 12.84 | $33.59B | Animal Health |
| 44 | GEHCGE HealthCare Technologies | 6.5% | 16.34 | $32.43B | Diagnostic Equipment |
| 45 | ALNYAlnylam Pharmaceuticals | 90.1%OUT | 41.52 | $30.44B | Biotechnology |
| 46 | DXCMDexcom | 15.5% | 29.76 | $29.75B | Medical Devices |
| 47 | WSTWest Pharmaceutical Services | 12.4% | 49.10 | $27.74B | Medical Supplies |
| 48 | LHLabcorp Holdings | 6.4% | 26.82 | $26.89B | Diagnostic Labs |
| 49 | DGXQuest Diagnostics | 9.1% | 23.61 | $26.65B | Diagnostic Labs |
| 50 | PHGKoninklijke Philips | 6.1% | 13.69 | $25.23B | Diagnostic Equipment |
| 51 | UTHRUnited Therapeutics | 2.5% | 19.11 | $25.05B | Pharmaceuticals |
| 52 | INCYIncyte | 26.9% | 14.07 | $22.69B | Pharmaceuticals |
| 53 | THCTenet Healthcare | 5.4% | 10.03 | $22.47B | Hospitals |
| 54 | STESteris | 8.4% | 27.79 | $22.37B | Medical Devices |
| 55 | MEDPMedpace Holdings | 20.4% | 36.44 | $18.87B | Contract Research |
| 56 | ZBHZimmer Biomet Holdings | 8.6% | 23.00 | $18.55B | Medical Devices |
| 57 | RVTYRevvity | 4.1% | 75.27 | $17.88B | Life Sciences Tools |
| 58 | EXELExelixis | 9.2% | 18.96 | $16.32B | Pharmaceuticals |
| 59 | SOLVSolventum | -0.9% | 10.40 | $14.92B | Medical Devices |
| 60 | HALOHalozyme Therapeutics | 41.2% | 36.01 | $14.89B | Biotechnology |
| 61 | ASNDAscendis Pharma A | 128.4%OUT | 17.14 | $14.86B | Biotechnology |
| 62 | NBIXNeurocrine Biosciences | 34.4% | 20.64 | $14.56B | Pharmaceuticals |
| 63 | ICLRIcon | 3.7% | 44.16 | $14.52B | Contract Research |
| 64 | FMSFresenius Medical Care AG | -47.8% | 12.11 | $13.24B | Healthcare Services |
| 65 | JAZZJazz Pharmaceuticals | 12.6% | 14.04 | $13.21B | Pharmaceuticals |
| 66 | PENPenumbra | 17.6% | 79.63 | $12.79B | Medical Devices |
| 67 | EHCEncompass Health | 9.5% | 19.73 | $12.25B | Hospitals |
| 68 | BTSGBrightSpring Health Services | 26.4% | 33.17 | $12.14B | Home Health and Senior Care |
| 69 | DVADavita | 6.4% | 14.06 | $11.92B | Healthcare Services |
| 70 | COOCooper Companies | 4.7% | 20.61 | $11.75B | Medical Devices |
| 71 | RDYDr Reddys Laboratories | -10.5% | 31.44 | $11.43B | Generic Drugs |
| 72 | TECHBio-Techne | -0.4% | 62.34 | $11.34B | Life Sciences Tools |
| 73 | UHSUniversal Health Services | 10.0% | 7.26 | $11.09B | Hospitals |
| 74 | GMEDGlobus Medical | 19.7% | 20.49 | $10.97B | Medical Devices |
| 75 | QGENQiagen | 3.0% | 26.74 | $10.95B | Life Sciences Tools |
| 76 | ALGNAlign Technology | 4.4% | 26.18 | $10.83B | Dental |
| 77 | BMRNBiomarin Pharmaceutical | 11.2% | 147.08OUT | $10.73B | Biotechnology |
| 78 | ENSGEnsign | 18.9% | 27.03 | $10.24B | Home Health and Senior Care |
| 79 | PODDInsulet | 29.4% | 27.17 | $10.20B | Medical Devices |
| 80 | RGENRepligen | 16.5% | 244.58OUT | $10.16B | Life Sciences Tools |
| 81 | BIOBio-Rad Laboratories | 1.4% | 44.81 | $9.97B | Life Sciences Tools |
| 82 | HSICHenry Schein | 6.5% | 23.78 | $9.58B | Drug Distribution |
| 83 | OSCROscar Health | 42.8% | 16.91 | $9.31B | Managed Care |
| 84 | PTGXProtagonist Therapeutics | 34.8% | 112.22 | $9.30B | Biotechnology |
| 85 | KRYSKrystal Biotech | 22.6% | 38.19 | $9.22B | Gene and Cell Therapy |
| 86 | CAICaris Life Sciences | 85.4%OUT | 87.39 | $9.19B | Diagnostic Labs |
| 87 | CORTCorcept Therapeutics | 16.0% | 168.41OUT | $9.13B | Pharmaceuticals |
| 88 | HNGEHinge Health | 49.8% | 82.00 | $8.80B | Telehealth |
| 89 | PACSPacs | 15.2% | 28.67 | $7.72B | Home Health and Senior Care |
| 90 | TGTXTg Therapeutics | 76.1% | 17.32 | $7.65B | Biotechnology |
| 91 | ALKSAlkermes | 10.8% | 111.78 | $7.39B | Pharmaceuticals |
| 92 | CHEChemed | 3.3% | 24.65 | $6.78B | Home Health and Senior Care |
| 93 | AMRXAmneal Pharmaceuticals | 9.3% | 42.81 | $6.74B | Generic Drugs |
| 94 | LNTHLantheus Holdings | 2.3% | 23.66 | $6.51B | Diagnostic Equipment |
| 95 | LGNDLigand Pharmaceuticals | 54.9% | 31.00 | $6.11B | Biotechnology |
| 96 | MMSIMerit Medical Systems | 10.2% | 38.56 | $5.61B | Medical Devices |
| 97 | KNSAKiniksa Pharmaceuticals International | 58.9% | 69.27 | $5.59B | Biotechnology |
| 98 | HAEHaemonetics | 0.4% | 55.72 | $5.37B | Medical Devices |
| 99 | STVNStevanato Group S.p.A | 14.8% | 34.04 | $5.34B | Medical Supplies |
| 100 | SHCSotera Health | 8.1% | 32.03 | $5.24B | Diagnostic Labs |
Among Healthcare stocks, the largest companies growing revenue faster than the median (10.2%) while trading below the median P/E (24.75) are Gsk (GSK), Boston Scientific (BSX), Sanofi (SNY), Incyte (INCY) and Ascendis Pharma A (ASND). A low multiple next to fast growth can be an opportunity or a sign the market doubts the growth will last.
The largest companies with a P/E above the median and revenue growth below it are Johnson & Johnson (JNJ), Unitedhealth (UNH), Merck (MRK), Astrazeneca (AZN) and Thermo Fisher Scientific (TMO).
The median P/E across the 213 Healthcare stocks plotted is 24.75, with the middle half between 13.22 and 41.52.
The median is 10.2%, with the middle half between 4.1% and 24.3%.
The rank correlation (Spearman) is 0.08, a no meaningful positive relationship: knowing one tells you little about the other.
A company whose value lies more than three interquartile ranges beyond the first or third quartile is treated as an outlier. By default it stays on the chart, pinned to the edge as an open marker, and its true value is shown in the tooltip and the table. In this view 17 companies are outliers on Revenue Growth (1y) (TTM) and 12 on P/E. You can switch to percentile clamping, exclude outliers, or plot raw values on a log scale.
Metrics from Business Quant's screener: trailing-twelve-month figures from SEC filings and multiples on the latest close. A company appears once even when it lists more than one share class. A company with a secondary business line in this sector is included unless you choose primary industry only. Nothing on this page is investment advice.